PMCTPharmaCountry
    Home
Research & ReportsAug 30, 2026•1 min read

AI in Pharma Faces Data‑Gathering Delays, Not Scientific Limits

By the PharmaCountry team

A recent note says most of the two‑week deviation investigation time is spent on data collection, not science, highlighting a bottleneck for AI tools in pharma.

Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.

Compiled by the PharmaCountry team · Source: FiercePharma

Topics:#AI#pharma#data management#deviation investigation#regulatory compliance

More articles

View all insights
Research & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory Updates
Korea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
Analysis
Pharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026